A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03849469

Recruitment Status : Completed

First Posted : February 21, 2019

Last Update Posted : March 30, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

ICON Clinical Research

Information provided by (Responsible Party):

Xencor, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	February 16, 2023
Actual Study Completion Date :	February 16, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wong RL, Yu EY. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. Curr Treat Options Oncol. 2021 Jan 12;22(2):13. doi: 10.1007/s11864-020-00808-x.

To Top